Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 6 May 2024 |
| Trading in Novo Nordisk shares by board members, executives and associated persons | 6 May 2024 |
| Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons | 3 May 2024 |
| Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024 | 2 May 2024 |
| Novo Nordisk A/S - share repurchase programme | 1 May 2024 |
| Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 | 26 Apr 2024 |